Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: receptor-associated protein therapeutics - Horizon Therapeutics plc

Drug Profile

Research programme: receptor-associated protein therapeutics - Horizon Therapeutics plc

Alternative Names: AmpTide; HepTide; NeuroTrans; RAP peptide; RAP-2s; RAP-NGF conjugates; Receptor-Associated Protein-Nerve Growth Factor conjugates

Latest Information Update: 16 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Raptor Pharmaceuticals Corp
  • Developer Horizon Therapeutics plc; Raptor Pharmaceutical Corp
  • Class
  • Mechanism of Action Growth factor receptor modulators; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C; Liver cancer; Mesothelioma; Neurodegenerative disorders

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 04 Nov 2017 No recent reports of development identified for preclinical development in liver cancer in USA (Parenteral)
  • 12 Aug 2014 HepTide™ is still in preclinical development for liver cancer in USA
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top